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Abstract: 
Introduction 
Neurocognitive dysfunction is a major symptom feature of schizophrenia and bipolar disorder. A 
prognostic relationship between cognition and community outcomes is well-documented in 
schizophrenia and increasingly recognized in bipolar disorder. However, specific associations 
among neurocognition, diagnosis, state symptomatology, and community functioning are 
unclear, and few studies have compared these relationships among patients with affective and 
non-affective psychoses in the same study. We examined neurocognitive, clinical, and 
community functioning in a cross-diagnostic sample of patients with psychotic disorders over a 
6-month follow-up interval. 
Method 
Neurocognitive, clinical and community functioning were assessed in participants with 
schizophrenia (n = 13), schizoaffective disorder (n = 17), or bipolar disorder with psychosis 
(n = 18), and healthy controls (n = 18) at baseline and 6 months later. 
Results 
Neurocognitive functioning was impaired in all diagnostic groups and, despite reductions in 
primary symptoms, did not recover on most measures over the follow-up period. Neurocognitive 
impairment was not associated with diagnosis or clinical improvement. Several neurocognitive 
scores at baseline (but not diagnosis or clinical baseline or follow-up scores) predicted 
community functioning at follow-up. 
Discussion 
In one of the few studies to longitudinally examine neurocognition in association with clinical 
and outcomes variables in a cross diagnostic sample of psychotic disorders patients, 
neurocognitive deficits were pronounced across diagnoses and did not recover on most measures 
despite significant reductions in clinical symptoms. Baseline neurocognitive functioning was the 
only significant predictor of patients' community functioning six months later. Efforts to 
recognize and address cognitive deficits, an approach that has shown promise in schizophrenia, 
should be extended to all patients with psychosis. 
Bipolar | Schizophrenia | Schizoaffective | Neurocognitive | Comparative | Keywords: 
Longitudinal 
Article: 
1. Introduction 
Cognitive dysfunction is a core feature of schizophrenia (SZ), schizoaffective disorder (SZA), 
and bipolar disorder (BD) (Heinrichs and Zakzanis, 1998, Murphy and Sahakian, 
2001 and Mesholam-Gately et al., 2009). Some cross-sectional comparisons indicate that 
cognitive deficits are qualitatively similar but quantitatively different across diagnostic 
categories (typically: SZ < BD, SZA) (Altshuler et al., 2004,Krabbendam et al., 
2005 and Reichenberg et al., 2008). However, others report no differences between groups 
(Balanza-Martinez et al., 2005, Lewandowski et al., 2011a and Simonsen et al., 2011). 
Cognitive impairment in adults with SZ appears to be significant but relatively stable (e.g. Hoff 
et al., 2005), although some cross-sectional evidence suggests that neurocognition may worsen 
with illness progression (Pukrop et al., 2006). Neurocognitive deficits in BD seem to present 
early in illness and remain largely stable (Mora et al., 2012 and Torrent et al., 2012). A meta-
analysis of neurocognition in euthymic BD showed deficits in most domains with medium to 
large effect sizes (Mann-Wrobel et al., 2011). However, some findings suggest that impairments 
are associated with illness duration and disease course (Denicoff et al., 1999 and Robinson and 
Ferrier, 2006). Few studies have compared neuropsychological functioning across diagnostic 
groups longitudinally. A study of older adults with SZ or BD found similar trajectories of 
neurocognitive decline but greater variability in patients with BD (Depp et al., 2007). A three-
year follow-up comparing patients with SZ and BD found that groups did not differ on most 
neuropsychological measures (Balanza-Martinez et al., 2005). 
Cognition is associated with poorer functional outcomes in SZ, and an increasing literature 
supports the same relationship in BD (e.g. Green, 2006, Bowie et al., 2010 and Mora et al., 
2012). A recent meta-analysis reported that the strength of associations between cognition and 
community functioning was similar between patients with SZ or BD (Depp et al., 2012). 
We examined neurocognitive, clinical, and community functioning in patients with SZ, SZA, or 
bipolar disorder with psychosis (BDP) over time. We have previously reported that at baseline 
all three patient groups exhibited significant and similar neurocognitive deficits (Lewandowski et 
al., 2011a). We hypothesized that a) all patient groups would exhibit deficits in neurocognition at 
follow-up, which would not differ by diagnosis, b) any observed cognitive change would not be 
associated with diagnosis or clinical state, and c) cognitive deficits at baseline, but not diagnosis 
or clinical symptoms, would predict community functioning at follow-up. 
2. Method 
2.1. Participants 
Participants with SZ (n = 13), SZA (n = 17) or BDP (n = 18), and healthy controls (n = 18) ages 
18–55 were recruited through the Schizophrenia and Bipolar Disorder Program at McLean 
Hospital. All procedures were approved by the McLean IRB. The present sample includes only 
subjects who returned for follow-up (56% of the initial sample). Non-completion was due 
primarily to an inability to re-contact subjects (39%). Four subjects (5%) declined to participate 
in the follow-up. The present subsample did not differ from the baseline sample on any 
demographic characteristics or clinical measures; however, fewer patients with SZ were 
inpatients at baseline (68% vs. 38%). 
2.2. Materials 
Clinical assessment included the Young Mania Rating Scale (YMRS), the Montgomery–Asberg 
Depression Rating Scale (MADRS), and the Positive and Negative Syndrome Scale (PANSS). 
Cognitive measures included the Brief Visuospatial Memory Test-Revised (BVMT), Hopkins 
Verbal Learning Test (HVLT), Trails A and B, Stroop Color and Word Test (Stroop), and 
Category Fluency. Community functioning was assessed using the Multnomah Community 
Ability Scale (MCAS), which measures daily living, social involvement and interest, and 
occupational/other meaningful activity. We administered an abbreviated version, eliminating 
items that assessed clinical symptoms (M3, M4, M17), substance abuse (M16), and intellectual 
functioning (M2) so as to measure community functioning in a way that was less directly 
associated with clinical and cognitive symptoms. The final version included 11 items scored 1–5 
(5 indicating highest functioning) for a total of 55 points. 
2.3. Procedures 
Ascertainment, diagnostic and baseline procedures are described in detail elsewhere 
(Lewandowski et al., 2011a). Briefly, participants completed assessments at baseline and 
approximately 6 months later. Diagnosis was established using the SCID interview. All 
participants were prescribed psychiatric medications at the time of 
assessment. Chlorpromazine (CPZ) equivalents were calculated based on the recommendations 
of Baldessarini (2012). 
2.4. Statistical approach 
Subjects were compared on demographic, clinical, and cognitive variables using ANOVA 
(continuous variables) or Chi-Square (categorical variables). Effect sizes were calculated 
(Cohen's d) for cognitive variables. Neuropsychological variables were normed using published 
data and converted to standard scores. A neuropsychological composite score was calculated for 
each subject and change scores were calculated for neuropsychological and clinical variables. 
Linear regressions were conducted predicting neuropsychological change using diagnosis or 
clinical change as predictors, accounting for number of lifetime hospitalizations, inpatient vs. 
outpatient status at baseline, and CPZ equivalents. To examine community outcomes at follow-
up, linear regressions were conducted predicting MCAS using baseline cognition and baseline or 
follow-up clinical variables as predictors after accounting for diagnosis and the above 
confounders. 
3. Results 
Patients did not differ by group on any demographic variable at baseline (Table 1). A greater 
proportion of patients with BDP were inpatients (BDP > SZ, SZA; p < .05). Groups differed on 
MCAS scores at baseline (BDP, SZA > SZ; p < .05) ( Table 2). At follow-up, groups differed on 
PANSS P (SZ > SZA > BDP; p < .05) and MCAS (BDP, SZA > SZ; p < .05). Patients with BDP 
showed greater improvement on the YMRS (p < .05). 
Table 1. Demographic variables by diagnosis. 
 SZ (n = 13) SZA (n = 17) BDP (n = 18) HC (n = 18) Test statistic 
Age 42.2 (8.9) 40.0 (8.4) 34.9 (12.8) 41.5 (8.5) 2.08* 
Educationa 4.0 (1.2) 4.6 (1.7) 4.7 (1.0) 6.3 (1.4) 1.01*** 
% Caucasian 69% 82% 89% 72% 1.94 
% female 23% 53% 56% 39% 3.74 
# Lifetime hosp. 4.8 (2.0) 4.8 (1.8) 3.8 (1.9) n/a 1.52 
% inpatient 38% 41% 75% n/a 6.49* 
Education: HC > SZ, SZA, BDP, p < .01. 
Age: HC > BDP, p < .05. 
Inpatient: BDP > SZ, SZA, p < .05. 
aEducation is coded based on the SCID Education and Work History scale: 1 = grade 6 or less; 
2 = grade 7–12 (without graduating); 3 = high school grad or equivalent; 4 = part college; 
5 = graduated 2 year college; 6 = graduated 4 year college; 7 = part graduate/professional school; 
8 = completed graduate/professional school.  *p < .05. ***p < .001. 
Table 2. Clinical variables by diagnosis. 
 SZ (n = 13) SZA (n = 17) BDP (n = 18) F-statistic 
Baseline 
MCAS 39.3 (8.5) 45.1 (7.7) 47.7 (7.0) 4.21* 
YMRS 11.5 (10.3) 13.1 (11.9) 20.7 (15.4) 2.28 
MADRS 10.1 (7.6) 11.0 (8.8) 14.6 (11.7) 0.97 
PANSS P 18.7 (8.6) 16.9 (8.3) 16.2 (7.1) 0.38 
PANSS N 14.0 (3.9) 11.5 (4.4) 10.7 (7.1) 1.43 
PANSS G 28.0 (8.4) 26.8 (9.2) 30.7 (11.4) 0.71 
CPZE 534 (402) 476 (384) 294 (294) 1.62 
 Follow-up 
MCAS 42.6 (6.6) 46.4 (5.1) 48.6 (6.1) 3.80* 
YMRS 9.3 (11.5) 8.1 (6.3) 6.9 (6.3) 0.35 
MADRS 9.4 (8.4) 10.7 (8.3) 10.5 (12.0) 0.07 
PANSS P 17.2 (8.0) 14.8 (5.7) 10.8 (3.5) 4.66* 
PANSS N 14.0 (5.1) 13.6 (7.0) 10.7 (3.0) 1.98 
PANSS G 28.8 (11.8) 24.9 (6.9) 23.5 (7.0) 1.54 
 Change scores 
MCAS 3.3 (4.6) 1.0 (9.4) 1.7 (5.4) 0.40 
YMRS − 2.2 (11.3) − 5.1 (12.6) − 14.0 (15.7) 3.23* 
MADRS − 0.8 (7.4) − 0.3 (8.1) − 4.1 (12.0) 0.80 
PANSS P − 1.5 (6.0) − 2.1 (9.3) − 5.9 (6.7) 1.60 
PANSS N 0.0 (6.0) 2.1 (6.2) 0.0 (7.6) 0.52 
PANSS G 0.8 (6.8) − 1.9 (10.7) − 7.2 (11.3) 2.65 
MCAS: Multnomah Community Ability Scale; YMRS: Young Mania Rating Scale; MADRS: 
Montgomery–Asberg Depression Rating Scale; PANSS: Positive and Negative Syndrome Scale; 
CPZE: CPZ Equivalents. *p < .05. 
Cognitive data are presented in Fig. 1. At baseline and follow-up groups differed only on Trails 
B (BDP, SZA > SZ; p < .05). Groups differed in neurocognitive improvement over the follow-up 
only on the BVMT-R (BDP > SZA; p < .05) and Stroop Interference (BDP > SZA; p < .05). 
Control participants differed from patient groups on all neuropsychological measures at baseline 
and follow-up (p = .013–p < .001); controls and patients did not differ on change scores. At Time 
1 Trails B showed medium effects (SZ vs. SZAd = .67; SZ vs. BDP d = .73). At Time 2 Trails B 
showed large effects (SZ vs. SZA d = .75; SZ vs. BDPd = .90) as did the Composite (SZ vs. 
BDP d = .78); we found several medium effects including HVLT (SZ vs. SZA, d = .60; SZ vs. 
BDP d = .72), Stroop Color (SZ vs. BDP d = .63), and Stroop Interference (SZA vs. 
BDP d = .64). Change BVMT and Stroop Interference scores showed medium effects (SZA vs. 
BDP d = .70 and SZA vs. BDP d = .72 respectively). 
 
Fig. 1.  Age-adjusted z-scores for neuropsychological variables by diagnosis. BVMT: Brief 
Visuospatial Memory Test-Revised, HVLT: Hopkins Verbal Learning Test-Revised, Categories: 
Category Fluency (Animals), Stroop C: Stroop Color, Stroop C-W: Stroop Color-Word. 
Linear regressions revealed that diagnosis did not predict cognitive change for the 
neurocognitive composite or any neurocognitive variable after accounting for severity measures 
and CPZ equivalents. Similarly, clinical change did not predict neurocognitive change for any 
neurocognitive measures. All neurocognitive scores at baseline predicted the neurocognitive 
composite at follow-up (p < .05–p < .001). 
MCAS and neurocognitive data were correlated at both time points (p < .01 for all associations; 
baseline r = 0.27–0.40; follow-up r = 0.34–0.63). Baseline neurocognitive scores were 
significantly correlated with follow-up MCAS scores (r = 0.38–0.60, p < .01). Linear regressions 
predicting MCAS scores at follow-up revealed that several baseline neurocognitive variables 
predicted MCAS at follow-up even after accounting for severity and diagnosis ( Fig. 2). Baseline 
BVMT (β = 1.43; t = 2.25, p < .05), Trails A (β = 2.26; t = 2.13,p < .05), and Stroop 
Interference (β = 2.31; t = 2.24, p < .05) predicted follow-up MCAS; the composite (
β = 2.27; t = 1.99, p = .05) and Stroop Color (β = 2.31; t = 1.93, p = .06) approached 
significance. Clinical measures including diagnosis, baseline and follow-up clinical variables did 
not predict MCAS at follow-up. 
 
Fig. 2. Cognitive scores at baseline by community functioning at follow-up. 
4. Discussion 
Patients with SZ, SZA, and BDP exhibited cognitive deficits at baseline, which remained largely 
unchanged six months later despite clinical improvement in other domains. Indeed, of the change 
scores that revealed medium to large effects, one was in a worsening direction (BVMT: SZA 
T2 < T1). Patients with SZ performed significantly worse than patients with BDP or SZA on 
Trails B at baseline and follow-up. No other group differences were observed at either time 
point. Effect sizes at both time points and change scores were typically in the small range for 
most non-significant findings although medium effects on HVLT, Stroop Color and Stroop 
Interference at follow-up were suggestive of better performance in the BD group on these 
measures. Patients with BDP evidenced greater improvement than patients with SZA on 
visuospatial memory and Stroop Interference. No other group differences in cognitive change 
were observed. 
Community functioning was impaired in all patient groups at both assessment points; however, 
patients with SZ scored significantly worse than the other two patient groups at both 
assessments. Cognitive functioning at baseline predicted community functioning at follow-up 
even after accounting for diagnosis and symptom severity. Community functioning at follow-up 
was not predicted by diagnosis or clinical presentation. These findings support the concept of a 
core neurocognitive dimension that cuts across diagnostic boundaries, is relatively independent 
of clinical symptoms, and contributes in a similar way to community outcomes in patients with 
SZ, SZA or BDP. 
Our study is limited by a small sample size, short follow-up duration, and a relatively high 
sample attrition. However, the follow-up subsample did not differ from the total sample on most 
measures. Cognitive functioning may improve along a flatter trajectory than clinical symptoms. 
Nonetheless, the observation that symptoms improved but cognition did not suggests a 
decoupling of these dimensions. 
The present findings suggest that patients with SZ, SZA, and BDP show similar neurocognitive 
deficits that do not fully recover in most domains over time, regardless of diagnosis or symptom 
change. Additionally, cognitive functioning was the only significant predictor of community 
outcomes in all patient groups. Treatments targeting neurocognitive dysfunction hold the 
promise of improving outcomes for all patients with psychotic disorders suffering from 
neurocognitive deficits (Lewandowski et al., 2011b). Additionally, identification of shared 
symptom dimensions such as neurocognition may improve understanding of the nature of brain 
abnormalities underlying psychotic disorders. 
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